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1. Introduction 
1.1 Epidemiology of diabetic retinopathy 
Among diverse microvascular complications of diabetes, diabetic retinopathy is a leading 
cause of adulthood blindness in the United States. According to the report of Eye Diseases 
Prevalence Research Group, the estimated incidence of diabetic retinopathy reaches up to 
3.4% in US general population (Kempen et al., 2004). The incidence of retinopathy is 
increasing according to the duration of diabetes. In type I diabetes patients with duration of 
20 years or more, the prevalence of any diabetic retinopathy reaches 100% (Klein et al., 
1984b). Diverse classification criteria was introduced in diabetic retinopathy, but the 
presence of retinal new vessel (definition: any new vessels arising from retina or optic disc, 
extending to the inner surface of retina or into the vitreous cavity) is the most frequently 
used criterion because of its clinical significance. Panretinal photocoagulation is indicated in 
proliferative diabetic retinopathy (PDR) with high risk characteristics, where there is a 
dramatically increased risk of severe visual loss within 2 years (26.2%) compared to that of 
PDR without high risk characteristics (7%) (The Diabetic Retinopathy Study Research Group 
[ETDRS], 1987). 
1.2 Anatomical and functional changes involved in diabetic retinopathy 
The earliest clinical finding in diabetic retinopathy is the presence of microaneurysms 
and/or retinal dot hemorrhages. Pathologically, thickening of capillary basement 
membrane, loss of pericytes are early signs of diabetic retinopathy (Cunha-Vaz, 1978; 
Garner, 1993). Along with perivascular extracellular matrix, pericytes contribute to the 
stability of retinal microvessels. Pericytes share their basement membrane with retinal 
endothelial cells and postulated to mechanically stabilize retinal vasculature through N-
cadherin-mediated adherence junctions located in peg–socket contacts (Gerhardt & 
Betsholtz, 2003). Moreover, pericytes communicate with endothelial cell through several 
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mediators to regulate recruitment and proliferation of pericytes, proliferation of endothelial 
cells and the functional integrity of blood-retinal barrier. Loss of pericytes is putative cause 
of microaneurysm formation in diabetic retinopathy. In a more advanced stage, acellular 
capillaries and vitreo-retinal neovascularization are the characteristic histo-pathologic 
findings. Loss of retinal capillary cellular components involves both endothelial cells and 
pericytes. The mechanism of cell loss is to be elucidated, but throughout the diabetic retinal 
vasculature, increased apoptosis was observed in both animal models and human 
specimens (Mizutani et al., 1996). 
1.3 General patho-physiology of diabetic retinopathy 
In non-proliferative diabetic retinopathy, increased vascular permeability and retinal 
ischemia secondary to retinal capillary drop-out are two major patho-physiologic processes. 
Proliferation of new vessels and/or fibrous tissue is the hallmark of proliferative diabetic 
retinopathy. Unlike to normal retinal vessels, newly formed vessels in proliferative diabetic 
retinopathy are leaky due to the presence of endothelial fenestrae and incompetency of 
junctions (Wallow & Geldner, 1980; Williams et al., 1988) and usually accompany fibrous 
proliferation. These features of new vessels are responsible for the aggravation of retinal 
edema and development of retinal and/or vitreous hemorrhage in PDR patients. Moreover, 
a contraction of posterior vitreous surface which are adherent to the fibrovascular 
membrane usually results in the traction retinal detachment. In this chapter, we further 
discuss about the pathogenesis of diabetic retinopathy in an aspect of blood-retinal barrier 
dysfunction. 
2. Blood-retinal barrier: In health and disease (diabetic retinopathy) 
In the mammalian brain, molecular exchange between blood vessel and neuron is tightly 
regulated by the structure named blood-brain barrier (BBB). Ions, neurotransmitters, 
macromolecules like plasma proteins, toxins, metabolites and nutrients are regulated for 
neuronal homeostasis. Several mechanisms are involved in the selective exchange of 
molecule through BBB. There are two distinctive routes for circulating blood component to 
reach the central nervous system (CNS): transcellular and paracellular pathway (Pardridge, 
1999). Microvasculature of central nervous system is consisted with non-fenestrated 
endothelium sealed by intercellular adherent junction and tight junction. Under normal 
functioning BBB, paracellular pathway is restricted by these structures.  
As a part of CNS, retina also has functional barrier called blood-retinal barrier (BRB). Neural 
retina receives dual blood supply from retinal vessels and choroidal vessels. Retinal vessels 
and choroidal vessels are separated from neural retina by inner and outer BRB, respectively. 
In a narrow definition, inner BRB is a tight junction between retinal vascular endothelium 
(resembles the BBB proper of brain) and outer BRB means a tight junction between retinal 
pigment epithelium (resembles the blood-CSF barrier of brain). Among the two kinds of 
BRB, inner BRB is responsible for the pathogenesis of diabetic retinopathy.  
Inner blood-retinal barrier is composed of diverse cellular component including endothelial 
cells, pericytes and Müller cells. Pericytes ensheathe the retinal microvascular endothelium 
and share their basement membrane with endothelial cells. Pericytes are connected to 
endothelial cells through the N-cadherin mediated adherent junction. Müller cells have 
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spatial proximity with endothelium and communicate with endothelium through their foot-
processes. Each endothelial cell is interconnected with adjacent endothelial cell through 
tight junctions and adherent junctions to provide barrier function. Non-selective diffusion of 
molecules through the paracellular pathway is thightly regulated by those structures and 
limited exchange of molecules happens through the transcellular pathways (carrier 
mediated transport, transcytosis and lipophilic diffusion). 
 
Fig. 1. A schematic view of the inner blood-retinal barrier 
2.1 Molecular components of tight junction 
Tight junction is constituted by various kinds of proteins. Transmembrane proteins like 
occludin and claudin interconnect endothelial cell with adjacent endothelium and exert a 
barrier function (Furuse et al., 1998; Russ et al., 1998). Cytoplasmic accessory proteins like 
zonular occludens (ZO) 1-3, cingulin, 7H6 antigen and cadherin-5 connect transmembrane 
proteins to cytoskelecton (Gumbiner et al., 1991; Persidsky et al., 2006). Tight junction 
proteins not only function as a barrier regulating paracellular diffusion, but also work as 
signaling complex (Gonzalez-Mariscal et al., 2008). 
2.2 Molecular pathways across the BRB 
Molecular exchange across the inner BRB is allowed through paracellular pathway and 
transcellular pathway (Pardridge, 1999). Paracellular pathway is restricted by tight junction 
and limited exchange of substances occurs according to a concentration gradient. 
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Transcellular pathway involves diffusion of lipophilic molecule, carrier mediated transport 
and transcytosis (Abbott et al., 2006).  
2.3 Cellular components involved in the inner BRB 
2.3.1 Pericyte 
Retinal capillaries are covered by pericytes and pericytes exist in proximity to the 
endothelial cell (sharing basement membrane with endothelial cell). The spatial relationship 
facilitates the interaction of these two cells. Pericytes communicate with endothelial cells 
through diverse mediators like angiopoietins, transforming growth factor-ǃ (TGF-ǃ), 
platelet-derived growth factor-B (PDGF-B) and sphingosine-1-phosphate (S1P). Pericytes 
also form a heterocytic adherent junction with endothelial cells through N-cadherin 
(Navarro et al., 1998). In the retinal vasculature, the ratio of pericytes to endothelial cells is 
even higher than that of cerebral vasculature, reaching as high as 1:1.  
Recently, pericyte has been spotlighted as a key player in the development and functional 
maintenance of blood-neural barrier. According to recent reports, the presence of pericyte is 
indispensable for the functional integration of endothelial cell and Müller cell. Moreover, its 
coverage of capillaries correlates with BBB integrity (Shepro & Morel, 1993). Several in vitro 
studies suggested that pericyte is an important cellular component in BBB regulation. 
Pericyte derived angiopoietin-1 induces occludin expression in brain capillary endothelial 
cell via Tie-2 receptor activation (Hori et al., 2004). TGF-ǃ1/TGF-ǃ receptor signaling 
between pericyte and endothelial cell plays an important role in enhancing BBB function 
(Dohgu et al., 2005). PDGF-B/PDGF receptor- ǃ signaling is well known signal pathway 
involved in pericyte recruitment and proliferation during angiogenesis (Enge et al., 2002). 
For in vivo study, pericyte ablation model is needed, but Pdgfb -/- or Pdgfrb-/- mice, an 
ideal mural cell deficiency model, shows wide spread vascular leakage and hemorrhage 
leading to perinatal lethality (Leveen et al., 1994; Soriano, 1994). Perinatal lethality in these 
knock-out mice model made it difficult to analyze the role of pericyte in postnatal BBB 
dysfunction. More recently, studies using viable animal models of pericyte depletion 
provided an insight into the role of pericyte in BBB formation and regulation (Akagi et al., 
1983; Thanabalasundaram et al., 2010). 
The loss of pericyte is one of the earliest pathologic changes of diabetic retinopathy. The 
mechanism of pericyte loss in diabetic retinopathy is still unclear. Apoptosis triggered by 
hyperglycemia is presumed mechanism of pericyte loss in diabetic patients. Increased 
formation of advanced glycation end product (AGE) (Stitt et al., 1997) and aldose reductase 
expression in pericyte (Akagi et al., 1983) were suggested as the cause of pericyte loss under 
hyperglycemic condition. However, selective loss of pericyte is still to be elucidated because 
these mechanisms are common in various cell types. Pericyte loss not only results in the 
dysfunction of inner BRB, but also provides an important predisposing condition for the 
pathologic angiogenesis (Hammes et al., 2002). Under physiologic condition, pericytes 
inhibit the proliferation of endothelial cell. At the beginning of angiogenesis, the precedent 
denudation of pericytes from the pre-existing forefront of blood vessel is required for the 
mobilization of endothelial cells (Bergers & Benjamin, 2003; Yancopoulos et al., 2000). 
Endothelial hyperplasia which predispose for angiogenic sprouting can occur in the absence 
of pericytes. 
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2.3.2 Müller cells 
In the development of primate retina, glial cells enter into the retina from the optic nerve 
and invade to the peripheral retina. Glial cells are involved in diverse process of retinal 
vascular development. First, glial cells secrete VEGF in response to hypoxic condition, 
resulting in retinal vascularization (Kim et al., 2010b). Second, a growing body of evidences 
showed that Müller cell, a predorminant constituent of the retinal glial cell, forms 
‘neurovascular unit’ with endothelial cell and neuron to regulate blood flow of neural tissue 
and blood-neural barrier function. In vitro studies using retinal vascular endothelial cell co-
cultured with glial cell or cultured with conditioned medium from glial cell demonstrated 
that glial cell is important in barrier properties including the expression of tight junction 
proteins (Gardner, 1995; Gardner et al., 1997). Several glial cell derived growth factors like 
angiopoietin-1, basic fibroblast growth factor (bFGF), glial derived growth factor (GDGF) 
and TGF-ǃ are reported to induce the blood-neural barrier phenotype in vitro (Abbott et al., 
2006). The src-suppressed C kinase substrate (SSeCKS) expressed in glial cell regulates the 
barrier integrity by the regulation of VEGF (potent mediator of vascular permeability) and 
angiopoietin-1 (involved in vascular maturation and barriergenesis) level (Lee et al., 2003).  
Glial cell has a spatial proximity with endothelial cell and interconnected with basal laminar 
of endothelium via the end-foot processes. In the BBB, perivascular end-foot of glial cells 
contains abundant orthogonal arrays of particles (OAPs) in a polarized manner which is 
constituted with aquaporin 4 (AQP4) and the polarity of AQP4 localization in glial endfeet 
is disrupted under pathologic condition involving BBB impairment (Wolburg-Buchholz et 
al., 2009). In the perivascular endfeet of Müller cells, the expression of AQP4 also had been 
identified (Nagelhus et al., 1998). Agrin, an extracellular heparansulfate proteoglycan, is a 
factor that is known to affect this polarity of perivascular glial endfeet (Fallier-Becker et al., 
2011; Wolburg et al., 2009) and suggested to be participated in the BBB development (Barber 
& Lieth, 1997). 
Under diabetic condition both hypoxia and hyperglycemia can affect Müller cells leading to 
the breakdown of BRB. In the animal model of hypoxic retinopathy, hypoxia induced 
apoptotic loss of Müller cell leads to the subsequent BRB failure (Chan-Ling & Stone, 1992), 
pathologic angiogenesis and vitreous hemorrhage (Zhang & Stone, 1997). Moreover, in 
hypoxic retinopathy, Müller cell derived VEGF is essential pathogenic molecule resulting 
BRB disruption and pathologic neovascularization (Weidemann et al., 2010). Pathologic 
changes of retinal glia were also noted in the hyperglycemic condition. According to a study 
using streptozocin induced diabetic rat, Müller cell showed generalized regression 
throughout the retina from the early stage of diabetes before the BRB dysfunction (Rungger-
Brandle et al., 2000). Furthermore, in diabetic rat, the alteration of perivascular Müller glial 
aquaporins was noted especially in the superficial retinal vessels which might affect the 
barrier function (Iandiev et al., 2007). 
2.3.3 Endothelial cell 
Retinal capillaries are consisted by non-fenestrated endothelium and the basement 
membrane of retinal vascular endothelium is continuous. Tight junction between retinal 
micro-vascular endothelial cells is the anatomical basis of the inner BRB. Retinal vascular 
endothelium forms a homocytic interconnection with adjacent cell via tight junction and 
adherent junction. Beside tight junction, adherent junction stabilizes the BRB providing 
mechanical force. VE-cadherin is major molecule involved in endothelial-endothelial 
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adherent junctional complex (Navarro et al., 1998). The luminal side of retinal vascular 
endothelium has negative charge due to the glycocalyx coat which contributes to the barrier 
function toward negatively charged molecules and the loss of this surface charge causes 
dysfunction of BRB (Lin, 1988).  
Endothelial cell of retinal capillary expresses diverse transporters for selective molecular 
exchange between neural retina and circulation. Enzymatic activity vascular endothelial also 
contribute to barrier property through regulating the metabolism of substances from 
circulating blood to retina and vice versa. 
2.3.4 Neuron 
Retinal blood flow is tightly regulated according to the activity of retinal neurons. Metabolic 
need of ganglion cells is supposed to be an important factor in vascular development of 
retina. Intercellular communications between endothelial cells, Müller cells and neurons are 
expected to play a pivotal role in the formation and functioning of BRB. Diabetic retinopathy 
is a kind of progressive neuropathy. Retinal neuropathy in diabetes could be a consequence 
of preceding diabetic vascuopathy. However, there are some evidences that diabetes itself 
could be the cause of retinal neuropathy. In streptozocin induced early diabetic rats, 
increased apoptosis of neuron was documented especially in retinal ganglion cells and 
Müller cells (Hammes et al., 1995). Moreover, post-mortem human specimen from diabetic 
patients showed that apoptosis of neuronal cell could occur prior to clinically significant 
diabetic vasculopathy and the location of neuronal death had nothing to do with the 
presence of focal vascular lesions (Barber et al., 1998). These results suggest retinal neuronal 
apoptosis may not be the result of diabetic vasculopathy. 
3. Disruption of inner blood-retinal barrier in diabetic retina 
3.1 Protein Kinase C (PKC) 
In the diabetic retina, cellular accumulation of diacylglycerol which activates PKC to 
translocate into plasma membrane and to acquire phosphorylation activities has been 
documented (Dempsey et al., 2000; Newton, 1997; Xia et al., 1994). Hyperglycemia induced 
the activation of PKC is associated with the pathologic changes of diabetic retinopathy. The 
exact mechanism of PKC induced vascular leakage in diabetic retinopathy still remains 
unclear, but PKC, especillay ǃ-isoform is considered as a key mediator of VEGF induced 
BRB disruption and retinal neovascularization (Aiello et al., 1997; Xia et al., 1996). Recently, 
it is reported that PKCδ is also associated with the pathogenesis of diabetic retina through 
inducing the decrement of endothelial tight junction protein (ZO-1, 2) expression and 
subsequent vascular hyperpermeability in diabetic retina (Kim et al., 2010a). In addition, 
PKC mediated occludin phosphorylation is reported to participate in the VEGF stimulated 
vascular leakage (Harhaj et al., 2006). Some investigators also suggested nitric oxide (NO) 
pathway as a potential downstream target of PKC induced vascular permeability. In an 
experiment using coronary venule, PKC regulated vascular leakage partially relies on the 
endothelial NO synthesis (Huang & Yuan, 1997). 
3.2 Advanced Glycation Endproducts (AGEs) 
Long-term exposure to hyperglycemic environment results in a non-enzymatic glycation of 
protein, lipid and nucleic acid to form a heterogenous group of irreversible adducts called 
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AGEs. The clinical implication of AGEs is well documented in patients with diabetes. 
Among type 1 diabetic patients, skin levels of glycated collagen (Amadori product) and 
carboxymethyllysine (a kind of AGEs) showed correlation with the progression of diabetic 
retinopathy (Genuth et al., 2005). Vitreous level of hydroimidazolone, one of the most 
prominent AGEs, is reported to be increased in patients with type 2 diabetes (Fosmark et al., 
2007). 
AGEs and its receptor RAGE (receptor of AGEs) are known to exert a pivotal role in diabetic 
vascular complication such as retinopathy and nephropathy. Dysfunction of BRB in diabetic 
retinopathy is also caused by AGEs associated mechanism. First, dysfunction and apoptosis 
of pericyte, a key cellular component in the formation and maintenance of BRB are 
suggested as a mechanism of AGEs related BRB breakdown in diabetes. In streptozocin 
induced diabetic rats, significant deposition of AGEs and expression of RAGE were noted in 
pericytes of the capillary beds (Stitt et al., 1997). AGEs showed toxicity to pericyte in vitro 
and this toxic effect is mediated by AGE-RAGE interaction (Yamagishi et al., 1995). ROS 
generation through AGE-RAGE interaction results in oxidation of DNA, membrane lipid 
peroxidation and subsequent apoptotic pericyte death (Yamagishi et al., 2002b). In addition, 
AGEs regulate the expression of growth factors from pericyte which participate in the BRB 
function (Shimizu et al., 2011; Yamagishi et al., 2002a). Second, AGEs are involved in 
inflammatory reactions which cause the disturbance of BRB function. In diabetes, AGEs are 
accumulated in the vascular wall to stimulate proinflammatory reaction (Yan et al., 2003). 
These adducts not only activate leukocytes (Chibber et al., 2000) but also involved in the 
regulation of endothelial adhesion molecules. According to experimental study, blocking the 
interaction between AGEs and RAGE could effectively ameliorate retinal ICAM-1 
expression, leukostasis and subsequent BRB breakdown in diabetic animal (Kaji et al., 2007). 
Because diverse mechanisms are involved in the pathogensis of BRB breakdown in diabetic 
retinopathy, the evaluation on the effect of AGEs in non-diabetic indivisual is required for 
elucidating the role of AGEs in barrier dysfunction. In vivo studies using normo-glycemic 
animal showed that infusion of AGEs could induce vasculopathy resembling that of 
diabetes (Vlassara et al., 1992) and BRB breakdown associated with overexpression of VEGF 
(Stitt et al., 2000). 
3.3 Sorbitol 
Under hyperglycemia, glucose is converted to intracellular sorbitol by aldose reductase. 
Intracellular accumulation of sorbitol results in an osmotic damage to retinal vascular 
endothelium and pericytes. In a postmortem electron microscopic study of diabetic eye, BRB 
disruption and increased aldose reductase expression in the vascular cells participates in 
BRB formation (retinal vascular endothelial cells and Müller cells) were found which 
suggest that aldose reductase induced intracellular accumulation of sorbitol in vascular cell 
might contribute to the BRB breakdown in diabetes (Vinores et al., 1993). However, a 
randomized clinical trial of sorbinil, an aldose reductase inhibitor, in patients with diabetic 
retinopathy ended with little success in preventing retinopathy progression (Sorbinil 
Retinopathy Trial Research Group, 1990). 
3.4 Vascular Endothelial Growth Factor (VEGF) 
VEGF is not only a potent angiogenic growth factor, but also a strong vascular permeability 
enhancer. There are four different isoform of VEGF produced by alternative splicing of the 
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same gene: VEGF121, VEGF165, VEGF189 and VEGF206. Among these isoforms, VEGF165 is the 
predominant isoform with optimal characteristics of bioavailability and bioactivity (Ferrara 
et al., 2003). The expression of VEGF is regulated mainly by oxygen tension. Under hypoxic 
condition, hypoxia-inducible factor (HIF)-1 binds to hypoxia response element (HRE) of the 
VEGF gene and activates genes participate in cellular response to hypoxia (Carmeliet et al., 
1998; Jiang et al., 1996). VEGF expression is also controlled by diverse growth factors and 
inflammatory cytokines. In patients with proliferative diabetic retinopathy, vitreous level of 
VEGF is elevated and effectively reduced after panretinal laser photocoagulation (Aiello et 
al., 1994) because of a decreased metabolic need of neural retina which leads to amelioration 
of tissue hypoxia. Oxidative stress and pro-inflammatory cytokine is also suggested to be 
implicated in VEGF upregulation of diabetic retina (Frey & Antonetti, 2011; Giacco & 
Brownlee, 2010). VEGF exerts biological activity through specific receptor tyrosine kinases: 
VEGFR-1 and VEGFR-2. VEGFR-1 is considered as ‘decoy’ receptor which prevents VEGF 
from binding to VEGFR-2. Pro-angiogenic and vasopermeable effect of VEGF is mainly 
mediated by VEGF-2.  
VEGF induces retinal vascular hyperpermeability through both transcellular pathway and 
paracellular pathway. VEGF induces pinocytotic vesicular transport by upregulation of the 
vesiculo-vacuolar organelle (VVO) formation (Feng et al., 1999). In paracellular pathway, 
VEGF affects both of tight junction and adherent junction. The expression and assembly of 
tight junction protein ZO-1 and occludin are reduced by the VEGF (Antonetti et al., 1998; 
Wang et al., 2001). Post-translational regulation of tight junction protein by phosphorylation 
is also responsible for the VEGF mediated vascular hyperpermeability (Antonetti et al., 1999; 
Harhaj et al., 2006). Phosphorylation and disorganization of VE-cadherin, a major 
component of adherent junction between microvascular endothelial cells are another 
pathogenic change associated with VEGF induced vascular leakage (Esser et al., 1998; Kevil 
et al., 1998). Moreover, in patients with diabetic retinopathy, over-expressed VEGF 
upregulates adhesion molecules (ICAM-1, VCAM-1 and E-selectin) and enhances leukocyte 
adhesion (Kim et al., 2001). During the process of angiogenesis, local concentration of VEGF 
also perturbs pericyte coverage and maturation of blood vessels (Greenberg et al., 2008). In 
the animal model of diabetes, the VEGF mediated BRB breakdown and the restoration of 
BRB by an inhibition of VEGF action are well documented from the early stage of diabetic 
retinopathy (Murata et al., 1995; Qaum et al., 2001). Now a days anti-VEGF agents are 
widely used in the treatment of diabetic macular edema. 
3.5 Carbonic Anhydrase (CA) 
CA is a ubiquitous enzyme that catalyzes the interconversion of carbon dioxide and 
bicarbonate to regulate pH of tissue and to help transport of carbon dioxide. Presence of CA 
in the posterior segment of human eye has been proven (Wistrand et al., 1986), but the 
significance of CA in the pathogenesis of diabetic retinopathy was underestimated until 
recently. According to comparative proteomic analysis of vitreous from non-diabetic, 
diabetic without retinopathy versus proliferative diabetic retinopathy (PDR) subjects 
revealed that vitreous concentration of CA-I in PDR group was 15.3 and 8.2 times higher 
than that of non-diabetic and diabetic without retinopathy groups, respectively. In the rat, 
intravitreal injection of CA caused retinal vascular hyperpermeability through different 
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mechanism form that of VEGF induced barrier breakdown. Authors postulated that in 
diabetic retinopathy, increased CA elevates intraocular pH which in turn activates 
kallikrein-kinin system and subsequent bradykinin receptor activation leads to BRB 
breakdown (Gao et al., 2007). Moreover, in streptozocin-induced diabetic rats, decreased 
kallikrein-binding protein level has been noted (Hatcher et al., 1997), which could increase 
the free kallikrein level. CA inhibitors are potential candidate of supplementary treatment 
option for diabetic macular edema. Actually in a pilot study with a few participants, 
acetazolamide, a CA inhibitor, showed partial effect in improving diabetic macular edema 
(Giusti et al., 2001). 
3.6 Inflammation 
It is now generally accepted that the pathogenesis of diabetic retinopathy involves low 
grade inflammation and vascular endothelial dysfunction (Gerhardinger et al., 2005; Joussen 
et al., 2004; van Hecke et al., 2005). Leukostasis of retinal microvasculature was consistently 
found from the early stage of diabetic retinopathy. Several experimental and clinical 
evidences indicated that leukostasis is one of the most important causative factors of typical 
diabetic microvascular pathologies such as microvascular acellularity, capillary drop-out 
and microaneurysm formation (Kim et al., 2005; Lutty et al., 1997; McLeod et al., 1995). 
Moreover, leukostasis in diabetic retinopathy is closely associated with BRB breakdown 
(Leal et al., 2007). In the diabetic retina, upregulation of VEGF and increased inducible NO 
synthase activity is involved in the expression of endothelial adhesion molecules like ICAM-
1, VCAM-1 (Ishida et al., 2003; Leal et al., 2007; Nowak et al., 2008). Experimental study 
using ICAM knock-out mice revealed that adhesion molecule plays a key role in the 
endothelial dysfunction and barrier breakdown of diabetic retinopathy (Joussen et al., 2004). 
Several inflammatory cytokines are participated in the breakdown of BRB in diabetes. 
Interleukin-1 (IL-1)ǃ and tumor necrosis factor (TNF)-ǂ are the representative inflammatory 
cytokines participate in the pathogenesis of diabetic retinopathy. Both in the vitreous 
humour and serum of patients with proliferative diabetic retinopathy, the level of IL-1ǃ and 
TNF-ǂ is increased (Demircan et al., 2006). The activity of caspase 1 which is a proteolytic 
enzyme involved in the production of IL-1ǃ is also up-regulated in the retinas of diabetic 
patients (Mohr et al., 2002). IL-1ǃ is a well known cytokine that induces barrier dysfunction 
through leukocyte recruitment in diverse pathologic condition. High concentration of 
glucose stimulates endothelial IL-1ǃ over-expression and results in apoptosis of endothelial 
cell through the activation of NF-κB in vitro. Supplement of IL-1ǃ caused retinal 
microvascular change resembling that of diabetic retinopathy (Kowluru & Odenbach, 2004) 
and inhibition of caspase-1/interleukin-1beta signaling with minocycline prevented 
vascular pathology of diabetic rat (Vincent & Mohr, 2007). TNF-ǂ is also involved in the loss 
of retinal microvascular cells in diabetic retina (Behl et al., 2008). In bovine retinal 
endothelial cells, TNF-ǂ disturbs the expression of tight junction proteins (claudin-5 and 
ZO-1) and subcellular localization of these proteins (Aveleira et al., 2010). In the TNF-ǂ 
knock-out rat, diabetes associated retinal leukostasis, apoptosis of retinal microvascular cells 
and breakdown of BRB are significantly suppressed (Huang et al., 2011). Also in a diabetic 
rat, etanercept, a soluble tumor necrosis factor receptor (p75):Fc fusion protein (TNFR:Fc) 
effectively reduced leukostasis and breakdown of BRB (Joussen et al., 2002). 
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4. Clinical implication and current treatment modalities of diabetic inner BRB 
dysfunction: Diabetic macular edema 
Macular edema which resulted from the dysfunctional BRB is the most common cause of 
visual disturbance in patients with nonproliferative diabetic retinopathy (NPDR). In 
addition to the disruption of inner BRB of the pre-existing retinal vasculature, the ‘leaky’ 
property of new vessels contributes to the macular edema in patients with proliferative 
diabetic retinopathy (PDR). Breakdown of BRB causes retention of fluid and plasma 
contents, such as lipoproteins within neural retina leading to retinal thickening. According 
to the data of Wisconsin epidemiologic study of diabetic retinopathy (WESDRP), the 
prevalence of diabetic macular edema ranges from 18 to 20% among the patients with 
diabetes (Klein et al., 1984a; Klein et al., 1984b).  
After the reports of Early Treatment of Diabetic Retinopathy Study (ETDRS) focal/grid laser 
photocoagulation was the standard treatment method in diabetic macular edema. 
Stabilization or some improvement of vision was acquired in patients with macular edema 
who received laser photocoagulation. Although it is still the most cost-effective treatment 
modality in diabetic macular edema, some patients suffer from the post-treatment 
paracentral scotomas (Striph et al., 1988) and enlarging atrophic laser scars (Schatz et al., 
1991). Although rare, vision threatening complications like choroidal neovascularization 
and subretinal fibrosis were also reported (Cunningham & Shons, 1979). Because of the 
refractory macular edema and complications of laser treatment, several pharmacological 
treatment modalities had been introduced. Further delineation on the exact mechanism of 
action is still needed, but intravitreal steroid injection is a powerful treatment option in 
diabetic macular edema. There are many in vitro and in vivo studies suggesting the 
mechanisms involved in the effect of corticosteroid treatment for diabetic macular edema. 
An in vitro study using bovine retinal endothelial cell monolayer showed that 
hydrocortisone treatment reduced monolayer permeability to water and solutes, increased 
tight junction proteins (ZO-1 and occludin) and reduced occludin phosphorylation 
(Antonetti et al., 2002). In experimental diabetic retina, corticosteroids demonstrated 
differential regulation of VEGF receptors (down-regulation of VEGFR-2 and up-regulation 
of VEGFR-1, a ‘decoy’ receptor) (Zhang et al., 2008), inhibitory effects on VEGF, ICAM-1 
expression (Wang et al., 2008) and leukostasis (Tamura et al., 2005). Despite of the potential 
side effects like cataract and increased ocular pressure, intravitreal triamcinolone injection is 
one of the most commonly used treatment modality in diabetic retinopathy. More recently, 
several anti-VEGF agents are applicated in the treatment of diabetic macular edema. Several 
reports comparing the effectiveness of focal/grid laser photocoagulation, intravitreal 
triamcinolone injection and various anti-VEGF agents has been published (Diabetic 
Retinopathy Clinical Research Network, 2008; Soheilian et al., 2009), but more large scale 
studies with prolonged observation period are needed. 
5. Possible therapeutic approach to diabetic retinopathy through BRB 
modulation 
In addition to previously commented treatment modalities, diverse therapeutic agents had 
been suggested for the medical treatment of diabetic retinopathy through the modulation of 
inner BRB disruption. Clinical studies involving medical treatment of inner BRB dysfunction 
are summarized in table 1 and each therapeutic candidate is further delineated below. 
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Drug 
(Class) 
Suggested 
mechanism 
Clinical trials 
Study 
Population  
(N:enrolled/completed)
Result 
Fenofibrate 
(Fibrate) 
Inhibit VEGF 
production 
Reduce adhesion 
molecule level 
FIELD study 
Type 2 DM patients 
without requiring lipid 
modifying treatment 
(9795/9764) 
Reduced the risk of ME 
which needs laser 
treatment 
Lisinopril  
(ACE inhibitor) 
Inhibit VEGF 
production 
EUCLID 
Non-hypertensive type 1 
DM patients (530/354) 
No significant effect on 
the retinopathy 
progression 
Candesartan 
(AT1R blocker) 
Inhibit VEGF 
production 
DIRECT-
prevent 1 
Normoalbuminuric, 
normotensive type 1 DM 
patients (1421/1421) 
Reduce the risk of 
retinopathy 
DIRECT-
protect 1 
Normoalbuminuric, 
normotensive type 1 DM 
patients (1905/1905) 
No significant 
preventing effect on 
both retinopathy 
progression and ME  
development 
DIRECT-
protect 2 
Normoalbuminuric, type 
2 DM (1905/1905) 
Telmisartan 
(AT1R blocker) 
Reduce RAGE 
expression 
Untitled 
(Nakamura et 
al., 2005) 
Patients with essential 
hypertension (7/7) 
Decrease serum levels of 
sRAGE 
Ruboxistaurin 
(PKC inhibitor) 
Blocking VEGF 
mediated tight 
junction 
dysregulation 
PKC-DRS 
Patients with moderate 
to severe NPDR 
(252/157) 
No significant effect on 
both retinopathy 
progression and ME 
development Reduced 
the risk of MVL 
PKC-DRS2 
Patients with moderate 
to severe NPDR 
(685/514) 
Reduced the progression 
of ME into the center of 
macula and need for 
laser treatment for ME 
PKC-DMES 
Patients with DME 
farther than 300 μm 
from central macula, an 
ETDRS retinopathy level 
from 20 to 47A (686/506)
Preventive effect on ME 
progression 
Pimagedine 
(Aminoguani-
dine) 
Lowering AGEs 
production 
ACTION I 
trial 
Patients with type 1 DM 
(690/472) 
Significantly reduced the 
risk of three-step or 
greater progression of 
the retinopathy score 
Abbreviations 
ACTION I: A Clinical Trial In Overt Nephropathy of Type 1 Diabetics, AT1R: angiotensin II type 1 
receptor, DIRECT: Diabetic Retinopathy Cardesartan Trials, ETDRS: Early Treatment of Diabetic 
Retinopathy Study, DM: diabetes mellitus, EUCLID: EURODIAB Controlled Trial of Lisinopril in 
Insulin-Dependent Diabetes Mellitus, FIELD: Fenofibrate Intervention and Event Lowering in 
Diabetes, FU: follow-up, ME: macular edema, MVL: moderate visual loss, PKC-DRS: PKC inhibitor 
diabetic retinopathy study, PKC-DMES: PKC inhibitor diabetic macular edema study, sRAGE: soluble 
form of RAGE. 
Table 1. Possible medical therapeutic agent for the treatment of diabetic retinopathy through 
a modulation of inner BRB disruption 
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5.1 Fenofibrate 
Because dyslipidemia is a well documented risk factor of diabetic macular edema and hard 
exudates deposition, lipid lowering treatment was expected to have benefit on these 
complications. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 
group applicated fenofibrate, a peroxisome proliferator-activated receptor (PPAR)-ǂ agonist 
which is widely used as lipid lowering agent in diabetic patients to reduce the risk of 
microvascular and macrovascular complications. PPAR-ǂ agonist not only modulates lipid 
composition, but also inhibits the production of VEGF (Panigrahy et al., 2008) and reduces 
serum levels of adhesion molecule VCAM-1 and ICAM-1 (Rosenson et al., 2007) which are 
key components in the pathogenesis of BRB breakdown. Fenofibrate treatment 
demonstrated significant preventive effect on the hypoxia induced endothelial 
hyperpermeability of an in vitro BBB model (Mysiorek et al., 2009). In the type 2 diabetes 
patients without requiring lipid-modifying treatment, mean 5 years of fenofibrate (200 
mg/day) treatment significantly reduced the risk of macular edema development which 
needs laser treatment (31% reduction) (Keech et al., 2007). 
5.2 Blocking of the Retina-Angiotensin System (RAS)  
In human eye, the local expression of RAS components: renin, angiotensin converting 
enzyme (ACE) and angiotensin has been reported (Wagner et al., 1996) and their activation 
in diabetic retinopathy (Danser et al., 1989) is well documented. Increasing evidences 
indicate that angiotensin II stimulates the expression of VEGF in vitro (Williams et al., 1995). 
In streptozotocin-induced diabetic animal, ACE inhibitor treatment inhibited retinal VEGF 
production and subsequent retinal vascular hyperpermeability associated with BRB 
breakdown (Kim et al., 2009). Moreover, among the patients with proliferative diabetic 
retinopathy, vitreous level of VEGF is significantly lower in patients receiving ACE-
inhibition (Hogeboom van Buggenum et al., 2002). In diabetic hypertensive rat, treatment 
with candesartan, an angiotensin II receptor blocker effectively suppressed the vascular 
permeability across the BBB (Awad, 2006).  
On these experimental bases, several RAS inhibiting agents had been applicated for the 
treatment of diabetic retinopathy. The EURODIAB Controlled Trial of Lisinopril in Insulin-
Dependent Diabetes Mellitus (EUCLID) suggested that lisinopril, an ACE inhibitor could 
have benefit on the progression of diabetic retinopathy in patients with type 1 diabetes. 
However, the primary endpoint was the progression of diabetic retinopathy, and the 
protective effect does not showed statistical strength (Chaturvedi et al., 1998).  
The Diabetic Retinopathy Cardesartan Trials (DIRECT) group has performed three separate 
randomized, double-blind, placebo-controlled clinical trials to evaluate the efficacy of 
candesartan on reducing the incidence (DIRECT-Prevent 1), progression of retinopathy in 
type 1 (DIRECT-Protect 1) (Chaturvedi et al., 2008) and the progression of retinopathy in 
type 2 diabetes patients (DIRECT-Protect 2) (Sjolie et al., 2008). In both DIRECT-Protect 1 
and 2, the primary endpoint was progression of diabetic retinopathy, which was defined as 
three or more step deterioration of ETDRS level. Development of clinically significant 
macular edema (CSME), development of proliferative diabetic retinopathy or both were 
settled as secondary endpoint. Five years of candesartan treatment did showed significantly 
increased probability of diabetic retinopathy regression (34% increment) in type 2 diabetes 
patients, but there were no significant preventing effects on the progression of disease in 
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both type 1 and 2 patients. Although it was not the primary endpoint, the incidence of 
CSME development was not affected by candesartan treatment. 
5.3 Protein kinase C inhibitors 
Since Ishii et al. (Ishii et al., 1996) demonstrated that LY333531, a selective inhibitor of PKC 
ǃ-isoform could rescue diabetic animals from vascular dysfunction, several clinical studies 
on ruboxistaurin (orally active form of selective PKC ǃ inhibitor: LY333531) use for diabetic 
retinopathy had been performed: the PKC inhibitor diabetic retinopathy study (PKC-DRS), 
the PKC inhibitor diabetic retinopathy study 2 (PKC-DRS2), the PKC inhibitor diabetic 
macular edema study (PKC-DMES). PKC-DRS is a phase 3, multicenter, double-masked, 
placebo controlled trial involving patients with moderate to severe NPDR, the endpoints of 
which are progression of diabetic retinopathy (equal to or greater than three-step worsening 
in the ETDRS scale), moderate vision loss (MVL: vision decrease of three or more lines on 
the ETDRS chart) and sustained MVL (SMVL: MVL in two consecutive visit 6 or more 
months apart). Oral administration of ruboxistaurin (32 mg/day) for more than 36 months 
showed no preventive effect on the diabetic retinopathy progression, but significantly 
delayed the occurrence of MVL and SMVL and reduced the risk of MVL to one-third of that 
in the placebo group (The Protein Kinase C beta Inhibitor Diabetic Retinopathy Study [PKC-
DRS], 2005). According to PKC-DRS2, a following phase 3 clinical trial designed to evaluate 
visual outcome of ruboxistaurin treatment in patients with moderate to severe NPDR, 
administration of ruboxistaurin reduced a 3-year risk of SMVL from 9.1% to 5.5% (40% risk 
reduction). Moreover, ruboxistaurin reduced the progression of macular edema into the 
center of macula and need for laser treatment for macular edema (Aiello et al., 2006). PKC-
DMES, an multicenter, double-masked, randomized placebo controlled trial the endpoint of 
which was progression to sight threatening macular edema or application of 
photocoagulation for diabetic macular edema, revealed partial effect of ruboxistaurin on the 
progression of diabetic macular edema to a more severe form in patients with diabetic 
macular edema (The Protein Kinase C beta inhibitor diabetic macular edema study [PKC-
DMES], 2007). 
5.4 Blockade of AGE-RAGE pathway 
5.4.1 Lowering AGEs production 
Aminoguanidine is a prototype drug for the prevention of diabetes-induced AGEs 
formation in vivo (Brownlee et al., 1986). The pharmacological mechanism of 
aminoguanidine involves inhibition of NO synthases and semicarbazide-sensitive amine 
oxidase. Hammes et al. insisted aminoguanidine treatment effectively inhibited the retinal 
arteriolar accumulation of AGEs, prevented abnormal endothelial proliferation and pericyte 
loss in diabetic rat. Acellular capillaries and microaneurysms, typical pathologic findings of 
diabetic retinopathy were also reduced significantly in the aminoguanidine treatment group 
(Hammes et al., 1991). Administration of aminoguanidine effectively attenuated cellular loss 
and microthrombus formation of retinal vessels also in diabetic spontaneous hypertensive 
rats (Hammes et al., 1994). In these reports, authors adapted in situ detection of advanced 
glycosylation-specific fluorescence for the quantification of AGEs, which might not be 
specific for AGEs, but also detect other oxidation products. Kern et al. found that 
aminoguanidine treatment effectively reduces pericyte loss, formation of microaneurysms 
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and acellular capillaries, but inhibitory effect of retinal AGEs accumulation is not significant 
in diabetic dogs (Kern & Engerman, 2001). A randomized, placebo-controlled study in 
patients with type 1 diabetes mellitus showed that treatment with pimagedine, a kind of 
aminoguanidine significantly reduced the risk of three-step or greater progression of the 
retinopathy (ETDRS) score (Bolton et al., 2004). The exact pharmachologic mechanism of 
aminoguanidine in preventing diabetic retinopathy progression is still to be elucidated and 
more clinical trials are needed to clearly delineate the benefit of aminoguanidine treatment 
in diabetic retinopathy. 
5.4.2 Lowering RAGE expression 
Several commonly used therapeutic agents showed effects on the reduction of RAGE 
expression in vascular endothelial cell: thiazolidinediones (rosiglitazone and pioglitazone), 
calcium channel blocker (nifedipine), angiotensin II receptor blocker (telmisartan). 
Rosiglitazone and pioglitazone, kinds of thiazolidinediones, an anti-diabetic drug act by 
binding to peroxisome proliferator-activated receptors reduces basal and tumor necrosis 
factor-ǂ stimulated expression of RAGE in cultured human umbilical vein endothelial cells. 
Decreased RAGE by thiazolidinediones results in subsequent inhibition of AGEs stimulated 
expression of pro-inflammatory protein (Marx et al., 2004). Nifedipine, a calcium channel 
blocker inhibits RAGE upregulation in AGEs treated human umbilical vein endothelial cells 
to reduce AGEs induced ROS production (Yamagishi & Takeuchi, 2004). Telmisartan, an 
angiotensin II receptor blocker inhibits RAGE expression in cultured human microvascular 
endothelial cells in vitro and decreases serum soluble form of RAGE level in patients with 
essential hypertension (Nakamura et al., 2005). In vivo studies evaluating the effect of those 
agents on the inner BRB breakdown in diabetic retinopathy are needed. 
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